Skip to main content
All lobbying filings

Crossroads Strategies, LLC

Crossroads Strategies, LLC filed a Q3 report for Merck & Co., Inc. on October 17, 2026, reporting $40,000 in lobbying income.

Lobbying for Merck & Co., Inc. · developer, manufacturer and distributor of pharmaceuticals

As filed: CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.

All filings by Crossroads Strategies, LLC · Everything Merck & Co., Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; international taxation.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

 Bills named in this filing 3
  • H.R. 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S. 4784
    National Defense Authorization Act for Fiscal Year 2027
  • S. 891
    Bipartisan Health Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem